The goal of this proposal is to develop a safe, effective, acceptable, and affordable, dendrimer-based vaginal microbicide to reduce the risk of transmission of viral sexually transmitted infections. Dendrimers are monodisperse macromolecules with highly-branched, tree-like, single molecule, polymeric structures with a broad spectrum of antiviral actions. Fifty dendrimers will be screened, five characterized in more detail, and two formulated and evaluated for preclinical efficacy and safety in animal models genital herpes. HIV and HBV anti-viral activities will be evaluated outside of the SBIR. The ultimate goal is to select and develop a single dendrimer formulated for commercial use. Antimicrobial activities, toxicity, mechanisms of action, spermicidal activity, and in vitro antiviral activity will be systematically evaluated in anticipation of an IND submission for phase I clinical trials in humans.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
5R43AI047548-02
Application #
6349938
Study Section
Special Emphasis Panel (ZRG1-SSS-K (01))
Program Officer
Savarese, Barbara M
Project Start
2000-09-01
Project End
2003-02-28
Budget Start
2001-09-01
Budget End
2003-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$300,000
Indirect Cost
Name
Viridae Clinical Sciences (USA), Inc.
Department
Type
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45219
Bernstein, D I; Stanberry, L R; Sacks, S et al. (2003) Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother 47:3784-8